CB 839 (CAS 1439399-58-2)
Alternate Names:
CB-839 Telaglenastat 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide Telaglenastat [USAN]
CAS Number:
1439399-58-2
Molecular Weight:
571.60
Molecular Formula:
C26H24F3N7O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CB 839 (CAS 1439399-58-2) References
- Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. | Thompson, RM., et al. 2017. Oncotarget. 8: 35863-35876. PMID: 28415782
- The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. | Varghese, S., et al. 2021. Mol Cancer Ther. 20: 500-511. PMID: 33361272
- Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. | Wu, S., et al. 2021. Nat Cancer. 2: 189-200. PMID: 34085048
- Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis. | Jiang, B., et al. 2022. Mol Cell. 82: 1821-1835.e6. PMID: 35381197
- Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. | Best, SA., et al. 2022. Cell Metab. 34: 874-887.e6. PMID: 35504291
- GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors. | Li, Y., et al. 2022. Cancer Res. 82: 3223-3235. PMID: 35895805
- Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. | Paik, PK., et al. 2023. J Thorac Oncol. 18: 516-526. PMID: 36240971
- Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. | De Los Santos-Jiménez, J., et al. 2023. Cancers (Basel). 15: PMID: 36672480
- Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. | Timofeeva, N., et al. 2023. Front Oncol. 13: 1161254. PMID: 37228498
- The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. | Usart, M., et al. 2024. Blood Adv. 8: 2312-2325. PMID: 38295283
Inhibitor of:
AATC, ACAD-11, ASCT2, AsnRS, ASNSD1, Glut10, GLYATL3, GOT1L1, Id2, KGA_Gls, LAT1, and mSHMT.Activator of:
ACSVL4, Gemin4, Glutamine-rich 1, KNP-I, and PGDH.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CB 839, 10 mg | sc-507354 | 10 mg | $140.00 |